

## **FOR IMMEDIATE RELEASE**

### **David Y. Mitchell Takes Office as ASCPT President**

**Alexandria, Va. (January 23, 2019)** — On March 16, 2019, David Y. Mitchell, PhD, will begin his appointment as president of the American Society for Clinical Pharmacology and Therapeutics (ASCPT).

Dr. Mitchell is chief scientific officer at Nuventra Pharma Sciences and a consultant for the pharmaceutical and biotechnology industries. With more than 25 years of experience in clinical trial design, pharmacokinetic and pharmacodynamic data analysis, drug metabolism, and drug development, Dr. Mitchell has helped many companies successfully bring new drugs to market. Prior to his role as a consultant, Dr. Mitchell led development teams and clinical pharmacology sub-teams for Pfizer, Procter & Gamble Pharmaceuticals, OSI Pharmaceuticals, and Array Biopharma.



*Dr. David Mitchell*

Dr. Mitchell earned his PhD in pharmaceutical sciences from the University of Colorado. He completed a postdoctoral fellowship in the Department of Pharmacology, Toxicology, and Therapeutics at the University of Kansas School of Medicine.

For 22 years, Dr. Mitchell has been an active member of ASCPT, serving on the board of directors and Finance, Nominating, Webinar, and Education Committees. He is also a longtime volunteer leader for the American Association of Pharmaceutical Scientists, with past appointments including president, annual meeting chair, and chair of the Pharmacokinetics, Pharmacodynamics and Drug Metabolism Section's Executive Committee.

### **About ASCPT**

ASCPT is the leading forum for the discussion, development, and integration of clinical pharmacology, translational medicine, and therapeutics. A pillar of the scientific community for more than 100 years, ASCPT is committed to advancing the study and practice of translational medicine.

### **Contact:**

Sharon Swan, FASAE, CAE

CEO, ASCPT

703-836-6981, Ext. 100

[Sharon@ascpt.org](mailto:Sharon@ascpt.org)